Resultado de búsqueda
Hace 8 horas · This first-in-human, randomized trial demonstrates that combining radium-223 with pembrolizumab does not significantly impact the tumor microenvironment in patients with metastatic castration-resistant prostate cancer. Data highlight that upregulation of immune checkpoint molecules could impede the combination’s clinical efficacy.
